Indobufen (K 3920), a new inhibitor of platelet aggregation: Effect of food on bioavailability, pharmacokinetic and pharmacodynamic study during repeated oral administration to man

V. Tamassia, G. Corvi, L. M. Fuccella, E. Moro, G. Tosolini, E. Tremoli

Research output: Contribution to journalArticle

Abstract

The effect of food on bioavailability of indobufen tablets was investigated in 6 healthy volunteers. Subsequently, the same subjects took 100 mg b.i.d. for 7 days. Plasma levels and urinary excretion of indobufen were determined by GLC. Platelet aggregation induced by several concentrations of adrenaline was determined turbidimetrically at various times after the first and last doses. The absorption of indobufen tablets was not substantially impaired by the presence of food in the GI tract, although peak plasma levels and AUCs were slightly reduced after food. Pharmacokinetic analysis of plasma and urinary levels of indobufen did not indicate any change in drug disposition after repeated dosing. Adrenaline-induced platelet aggregation was markedly inhibited for up to 12 h after the first dose and the intensity and duration of this effect did not change after repeated administration. A twice-daily dosing appears suitable for clinical trials.

Original languageEnglish
Pages (from-to)329-333
Number of pages5
JournalEuropean Journal of Clinical Pharmacology
Volume15
Issue number5
DOIs
Publication statusPublished - Sep 1979

Fingerprint

Platelet Aggregation Inhibitors
Biological Availability
Oral Administration
Pharmacokinetics
Food
Platelet Aggregation
Epinephrine
Tablets
Area Under Curve
Gastrointestinal Tract
Healthy Volunteers
Clinical Trials
indobufen
Pharmaceutical Preparations

Keywords

  • food effect on bioavailability
  • indobufen
  • pharmacodynamics
  • pharmacokinetics
  • platelet aggregation
  • repeated administration

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Indobufen (K 3920), a new inhibitor of platelet aggregation : Effect of food on bioavailability, pharmacokinetic and pharmacodynamic study during repeated oral administration to man. / Tamassia, V.; Corvi, G.; Fuccella, L. M.; Moro, E.; Tosolini, G.; Tremoli, E.

In: European Journal of Clinical Pharmacology, Vol. 15, No. 5, 09.1979, p. 329-333.

Research output: Contribution to journalArticle

@article{60d0ccbc15804e469c8a18e6ac95d599,
title = "Indobufen (K 3920), a new inhibitor of platelet aggregation: Effect of food on bioavailability, pharmacokinetic and pharmacodynamic study during repeated oral administration to man",
abstract = "The effect of food on bioavailability of indobufen tablets was investigated in 6 healthy volunteers. Subsequently, the same subjects took 100 mg b.i.d. for 7 days. Plasma levels and urinary excretion of indobufen were determined by GLC. Platelet aggregation induced by several concentrations of adrenaline was determined turbidimetrically at various times after the first and last doses. The absorption of indobufen tablets was not substantially impaired by the presence of food in the GI tract, although peak plasma levels and AUCs were slightly reduced after food. Pharmacokinetic analysis of plasma and urinary levels of indobufen did not indicate any change in drug disposition after repeated dosing. Adrenaline-induced platelet aggregation was markedly inhibited for up to 12 h after the first dose and the intensity and duration of this effect did not change after repeated administration. A twice-daily dosing appears suitable for clinical trials.",
keywords = "food effect on bioavailability, indobufen, pharmacodynamics, pharmacokinetics, platelet aggregation, repeated administration",
author = "V. Tamassia and G. Corvi and Fuccella, {L. M.} and E. Moro and G. Tosolini and E. Tremoli",
year = "1979",
month = "9",
doi = "10.1007/BF00558436",
language = "English",
volume = "15",
pages = "329--333",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Indobufen (K 3920), a new inhibitor of platelet aggregation

T2 - Effect of food on bioavailability, pharmacokinetic and pharmacodynamic study during repeated oral administration to man

AU - Tamassia, V.

AU - Corvi, G.

AU - Fuccella, L. M.

AU - Moro, E.

AU - Tosolini, G.

AU - Tremoli, E.

PY - 1979/9

Y1 - 1979/9

N2 - The effect of food on bioavailability of indobufen tablets was investigated in 6 healthy volunteers. Subsequently, the same subjects took 100 mg b.i.d. for 7 days. Plasma levels and urinary excretion of indobufen were determined by GLC. Platelet aggregation induced by several concentrations of adrenaline was determined turbidimetrically at various times after the first and last doses. The absorption of indobufen tablets was not substantially impaired by the presence of food in the GI tract, although peak plasma levels and AUCs were slightly reduced after food. Pharmacokinetic analysis of plasma and urinary levels of indobufen did not indicate any change in drug disposition after repeated dosing. Adrenaline-induced platelet aggregation was markedly inhibited for up to 12 h after the first dose and the intensity and duration of this effect did not change after repeated administration. A twice-daily dosing appears suitable for clinical trials.

AB - The effect of food on bioavailability of indobufen tablets was investigated in 6 healthy volunteers. Subsequently, the same subjects took 100 mg b.i.d. for 7 days. Plasma levels and urinary excretion of indobufen were determined by GLC. Platelet aggregation induced by several concentrations of adrenaline was determined turbidimetrically at various times after the first and last doses. The absorption of indobufen tablets was not substantially impaired by the presence of food in the GI tract, although peak plasma levels and AUCs were slightly reduced after food. Pharmacokinetic analysis of plasma and urinary levels of indobufen did not indicate any change in drug disposition after repeated dosing. Adrenaline-induced platelet aggregation was markedly inhibited for up to 12 h after the first dose and the intensity and duration of this effect did not change after repeated administration. A twice-daily dosing appears suitable for clinical trials.

KW - food effect on bioavailability

KW - indobufen

KW - pharmacodynamics

KW - pharmacokinetics

KW - platelet aggregation

KW - repeated administration

UR - http://www.scopus.com/inward/record.url?scp=0018360102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018360102&partnerID=8YFLogxK

U2 - 10.1007/BF00558436

DO - 10.1007/BF00558436

M3 - Article

C2 - 456404

AN - SCOPUS:0018360102

VL - 15

SP - 329

EP - 333

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 5

ER -